dc.creator | Castillo, Jorge J. | |
dc.creator | Beltran, Brady E. | |
dc.creator | Miranda, Roberto N. | |
dc.creator | Young, Ken H. | |
dc.creator | Chavez, Julio C. | |
dc.creator | Sotomayor, Eduardo M. | |
dc.date.accessioned | 2020-06-25T17:50:18Z | |
dc.date.accessioned | 2022-10-25T19:48:20Z | |
dc.date.available | 2020-06-25T17:50:18Z | |
dc.date.available | 2022-10-25T19:48:20Z | |
dc.date.created | 2020-06-25T17:50:18Z | |
dc.date.issued | 2018-07-09 | |
dc.identifier | Castillo JJ., Beltran BE., Miranda RN., Young KH., Chavez JC., Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018; 93(7): 953-962. | |
dc.identifier | 1096-8652 | |
dc.identifier | https://hdl.handle.net/20.500.12727/6261 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4797201 | |
dc.description.abstract | Disease overview
Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an aggressive B‐cell lymphoma associated with chronic EBV infection, and a poor prognosis with standard chemotherapeutic approaches.
Diagnosis
The diagnosis is made through a careful pathological evaluation. Detection of EBV‐encoded RNA is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined. The differential diagnosis includes plasmablastic lymphoma, DLBCL associated with chronic inflammation, primary effusion lymphoma, HHV8+ DLBCL, NOS, and EBV+ mucocutaneuos ulcer.
Risk‐stratification
The International prognostic index (IPI) and the Oyama score can be used for risk‐stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 is emerging as a potential adverse, and targetable, prognostic factor.
Management
Patients with EBV+ DLBCL, NOS, should be staged and managed following similar guidelines than patients with EBV‐negative DLBCL. EBV+ DLBCL, NOS, however, has a worse prognosis than EBV‐negative DLBCL in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV+ DLBCL, NOS. | |
dc.language | eng | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.relation | American Journal of Hematology;vol. 93, no. 7 | |
dc.relation | https://doi.org/10.1002/ajh.25112 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.source | Repositorio Académico USMP | |
dc.source | Universidad San Martín de Porres - USMP | |
dc.subject | Diagnóstico diferencial | |
dc.subject | Herpesvirus humano 4 | |
dc.subject | Linfoma de células B grandes difuso | |
dc.subject | Pronóstico | |
dc.subject | Medición de riesgo | |
dc.subject | Factores de riesgo | |
dc.title | EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk‐stratification and management | |
dc.type | Artículos de revistas | |